Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Common Equity (2016 - 2026)

Ekso Bionics Holdings has reported Common Equity over the past 14 years, most recently at $9.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 28.96% to $9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.0 million, a 28.96% decrease, with the full-year FY2025 number at $9.0 million, down 28.96% from a year prior.
  • Common Equity reached $9.0 million in Q4 2025 per EKSO's latest filing, down from $9.7 million in the prior quarter.
  • The five-year high for Common Equity was $41.0 million in Q1 2021, with the low at $9.0 million in Q4 2025.
  • The 5-year median for Common Equity is $16.5 million (2023), against an average of $22.0 million.
  • Peak YoY movement for Common Equity: surged 143300.0% in 2021, then tumbled 50.45% in 2023.
  • Tracing EKSO's Common Equity over 5 years: stood at $37.2 million in 2021, then tumbled by 31.64% to $25.4 million in 2022, then tumbled by 50.45% to $12.6 million in 2023, then grew by 0.8% to $12.7 million in 2024, then dropped by 28.96% to $9.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $9.0 million, $9.7 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.